If you would like to explore the possibility of participating in a clinical trial at Guthrie, please call 1-800-836-0388.

As a Guthrie cancer patient you will have the unique opportunity to participate in one or more of some 100 clinical research trials that involve new treatments for many cancer types.

As a Guthrie patient you may have the unique opportunity to take part in clinical research trials for atrial fibrillation, congestive heart failure, lipid disorders, heart attack and many more cardiology disease states.

As a Guthrie patient you may have an opportunity to take part in clinical research trials for celiac disease, Crohn’s disease, ulcerative colitis, reflux disease, hepatitis and many more gastroenterology disease states.

Clinical trials study new ways to prevent, detect and treat disease. If you take part in research, you help advance new investigational medical therapies. 

Title: S1802, "Phase III Randomized Trial of Standard Systemic Therapy (SST) Versus Standard
Systemic Therapy Plus Definitive Treatment (Surgery or Radiation) of the Primary Tumor
in Metastatic Prostate Cancer)."
Department: Oncology
Diagnosis: Genito-urinary - Prostate
Principal Investigator: Joyson Poulose, MD
Sponsors: NCI
Details (Indentifier #): 03678025
Title: S1827: MRI Brain Surveillance Alone Versus MRI Surveillance and Prophylactic Cranial Irradiation (PCI): A Randomized Phase III Trial in Small-Cell Lung Cancer (MAVERICK)
Department: Oncology
Diagnosis: Lung- Small Cell
Principal Investigator: Thomas J Gergel, MD
Sponsors: SWOG
Details (Indentifier #): NCT04155034
Title: S2015: Melanoma Margins Trial (MelMarT): A Phase III, Multi-Centre, Multi-National Randomised Control Trial Investigating 1cm v 2cm Wide Excision Margins for Primary Cutaneous Melanoma
Department: Oncology
Diagnosis: Melanoma
Principal Investigator: David Bertsch, MD, FACS
Sponsors: SWOG
Details (Indentifier #): NCT03860883
Title: S2302, PRAGMATICA - LUNG: A PROSPECTIVE RANDOMIZED STUDY OF RAMUCIRUMAB (LY3009806; NSC 749128) PLUS PEMBROLIZUMAB (MK-3475; NSC 776864) VERSUS STANDARD OF CARE FOR PARTICIPANTS PREVIOUSLY TREATED WITH IMMUNOTHERAPY FOR STAGE IV OR RECURRENT NON-SMALL CELL LUNG CANCER
Department: Oncology
Diagnosis: Lung- Non-Small Cell
Sponsors: CTSU -NCI
Details (Indentifier #): NCT05633602
Title: SALIX RNLC3131, A Randomized, Double-Blind, Placebo-Controlled, Multicenter Study to Assess the Efficacy and Safety of Rifaximin Soluble Solid Dispersion (SSD) for the Delay of Encephalopathy Decompensation in Cirrhosis (RED-C)
Department: Gastroenterology
Diagnosis: Gastrointestinal - Liver
Principal Investigator: Thomas J McDonald, MD
Sponsors: Salix
Details (Indentifier #): NCT05071716
Title: Tethered Enzyme Technology (TET) Assay for
Detection of COVID-19
Department: Internal Studies
Diagnosis: Infectious Disease
Principal Investigator: Sheela Prabhu, MD, FACP
Sponsors: Internal FDN
Details (Indentifier #): None
Title: Tethered Enzyme Technology (TET) Assay for Quantitative Diagnosis of Blunt Head Trauma (BHT) and Stroke through Detection of Blood and Saliva Biomarkers
Department: Trauma
Diagnosis: Neurology
Principal Investigator: Robert Behm, MD, FACS
Sponsors: Internal
Details (Indentifier #): None
Title: The CHRONICLE Study: A Longitudinal Prospective Observational Study of the Characteristics,Treatment Patterns and Health Outcomes of Individuals with Severe Asthma in the United States, D3250R000023
Department: Pulmonary
Diagnosis: Lung - Asthma
Principal Investigator: Louis R Dubois, MD
Sub-Investigator(s):
Sponsors: Astra Zeneca
Details (Indentifier #): NCT03373045
Title: The effect of Epinephrine in Irrigation Fluid for Visualization During Ankle Arthroscopy: A Randomized Blinded Controlled Trial
Department: Orthopedics
Diagnosis: Orthopedics
Sponsors: Internal
Details (Indentifier #): None
Title: The Efficacy of Steroid-Sparing Anti-Emetic Therapy in Patients Treated with High Emetogenic Chemotherapy; Single Center Non-Inferiority Open Label Randomized Controlled Trial
Department: Oncology
Diagnosis: Miscellaneous
Sub-Investigator(s):
Sponsors: Internal FDN
Details (Indentifier #): NCT05590923